Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC-SVT-1002
- Development stage
- Phase 2
- Lead developer
- Laboratorios Salvat
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Implant
01
Overview
HC-SVT-1002 is an allogeneic cell therapy product developed by Salvat for the treatment of atrophic pseudarthrosis (nonunion) of long bones. It consists of expanded allogeneic adipose-derived mesenchymal stem cells (AD-MSCs) combined with a tricalcium phosphate (TCP) biomaterial scaffold. The AD-MSCs provide osteogenic potential and secrete trophic factors to promote bone healing, while the TCP serves as an osteoconductive scaffold. This combination is designed to be applied surgically to the site of the nonunion to stimulate bone regeneration in cases where natural healing has failed.
- Other names
- Allogeneic Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial
Beyond the preview
Go deeper on HC-SVT-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HC-SVT-1002.